|
KMID : 0366219840190010029
|
|
Korean Journal of Hematology
1984 Volume.19 No. 1 p.29 ~ p.38
|
|
|
The Concentrations of the Serum Sialic Acid and Monocyte-mediated Antibody-dependent Cellular Cytotoxicity in Cancer Patients
|
|
승기배/K.B. Seung
이흥현/서재열/문한림/진종률/박종원/김춘추/김동집/H.H. Lee/J.Y. Suh/H.L. Moon/J.Y. Chin/C.W. Park/C.C. Kirn/D.J. Kim
|
|
|
Abstract
|
|
|
The concentrations of serum sialic acid was measured in the perchloric acid soluble
fraction of serum by the periodate-resorcinol method for clinical availability of alphal
acid glycoprotein level as a nonspecific marker of tumor.
Patients with malignancy showed significantly elevates serum levels of siails acid (135
±87.7 μg/㎖) compared with normal (38±8. 1 μg/㎖) and noncancer patients (69±35.0
μg/㎖) p<0.01).
Patients with advanced metastatic tumor were associated with significantly elevated
serum sialic acid level compared with localized cares. The correlation of sialic acid
content with progression of malignancy seemed quite plausible. To evaluate monocyte
mediated antibody-dependene cellular cytotoxicity (MMADCC), the standard 51Cr assay
system was applied, in which monocyte showed the sole effector function to the human
0 type(Rh+) erythrocytes(heterologous MMADCC), and patient's own erythrocytes
(autologous MMADCC) in the presence of isoantibody. The mean of cancer group was
reduced to 13.0±5.0% (p<0.01).
Chemotherapy elevated the MMADCC from 15.6±5.9% to 23. 1±7.0% (p<0.05). Slight
recovery of MMADCC by chemotherapy during the follow-up study of malignancy was
one of the internsting observation in our heterologous MMADCC system. But the same
result was not noticed when autologous erythrocytes were used as target cells.
There was no correlation between serum sialic acid level and MMADCC. These
findings suggests that serum sialic acid and MMADCC are a useful tumor marker for
the evaluation of clinical course and prognosis in cancer patients.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|